Secondary hyperparathyroidism (SHPT) is a chronic compensatory clinical manifestation, stimulated by long-term exposure to low blood calcium, low blood magnesium or high blood phosphorus. SHR6508, an allosteric modulator of calcium-sensing receptor, is developed to reduce parathyroid hormone (PTH) secretion among hemodialysis patients with SHPT. This first-inpatient study aimed to assess SHR6508 in Chinese patients with SHPT of chronic kidney disease on maintenance hemodialysis.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: